FDA approves first drug to treat adults with primary membranous nephropathy
The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.
Primary source
FDA approval notification, November 13, 2026
FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy
Read the source: FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy fda.gov
Machine-summarized from the source above; not independently reported. How we use automation